Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2018-07-06 Tx date 2018-06-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,234
+1,344 vol $23.24 each |
70,232 | |
Filed 2018-07-06 Tx date 2018-06-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,234
+1,344 vol $23.24 each |
24,801 | |
Filed 2018-07-06 Tx date 2018-06-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$27,492
+1,183 vol $23.24 each |
38,140 | |
Filed 2018-07-06 Tx date 2018-06-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$37,486
+1,613 vol $23.24 each |
73,707 | |
Filed 2018-05-28 Tx date 2018-05-23 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
-21,612 vol |
12,803 | |
Filed 2018-05-18 Tx date 2018-05-15 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$327,450
+15,000 vol $21.83 each |
109,926 | |
Filed 2018-05-11 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-186,684 vol |
300,335 | |
Filed 2018-05-11 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$3,418,184
+186,684 vol $18.31 each |
418,684 | |
Filed 2018-05-11 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-63,642.54
-3,522 vol $18.07 each |
94,926 | |
Filed 2018-05-11 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$459,086
+25,406 vol $18.07 each |
98,448 | |
Filed 2018-05-11 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-1,683,458.02
-91,942 vol $18.31 each |
326,742 | |
Filed 2018-05-11 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-25,406 vol |
23,457 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
68,888 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
57,109 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
72,094 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Power, Robert Noel
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
65,508 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Power, Robert Noel
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
36,957 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kavanagh, Sarah Baldwin
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
53,745 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kavanagh, Sarah Baldwin
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
56,013 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
48,863 | |
Filed 2018-05-10 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-09 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+13,881 vol |
13,881 | |
Filed 2018-05-09 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-07 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-07 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
14,285 | |
Filed 2018-05-07 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
||
Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
49,267 | |
Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
37,361 | |
Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kavanagh, Sarah Baldwin
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
54,149 | |
Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
56,417 | |
Filed 2018-05-04 Tx date 2018-05-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$390,528
+21,612 vol $18.07 each |
34,415 | |
Filed 2018-05-04 Tx date 2018-05-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-25,406 vol |
0 | |
Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
69,292 | |
Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
57,513 | |
Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
72,498 | |
Filed 2018-05-04 Tx date 2018-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Power, Robert Noel
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+14,285 vol |
65,912 | |
Filed 2018-04-06 Tx date 2018-03-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,235
+1,962 vol $15.92 each |
34,982 | |
Filed 2018-04-06 Tx date 2018-03-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$27,493
+1,727 vol $15.92 each |
23,076 | |
Filed 2018-04-06 Tx date 2018-03-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,235
+1,962 vol $15.92 each |
55,007 | |
Filed 2018-04-06 Tx date 2018-03-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$37,491
+2,355 vol $15.92 each |
58,213 | |
Filed 2018-03-29 Tx date 2018-03-26 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Indirect Ownership)
|
Bonds Corporate Bond 5.375% 03/15/2020
38 - Redemption, retraction, cancellation, repurchase
|
$
-$75,000,000 vol $1,013 each |
$0 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+22,162 vol |
72,849 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+113,652 vol |
487,019 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+511,434 vol |
511,434 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
97 - Other
|
-933,416 vol |
0 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$5,179,048
+338,058 vol $15.32 each |
1,020,710 | |
Filed 2018-03-14 Tx date 2018-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$481,500
+30,000 vol $16.05 each |
232,000 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+59,667 vol |
159,667 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+79,556 vol |
79,556 | |
Filed 2018-03-14 Tx date 2016-08-22 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$2,719,024
+177,482 vol $15.32 each |
1,177,482 | |
Filed 2018-03-14 Tx date 2018-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$241,469
+15,000 vol $16.10 each |
71,825 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+10,654 vol |
55,048 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+7,104 vol |
15,638 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$485,598
+31,697 vol $15.32 each |
63,127 | |
Filed 2018-03-14 Tx date 2018-03-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$153,400
+10,000 vol $15.34 each |
73,042 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+14,776 vol |
27,347 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,009,940
+65,923 vol $15.32 each |
96,097 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+20,457 vol |
66,071 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+13,638 vol |
48,136 | |
Filed 2018-03-14 Tx date 2018-03-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$932,267
+60,853 vol $15.32 each |
160,667 | |
Filed 2018-03-09 Tx date 2018-03-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson International Ltd (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-28,349,844.60
-1,840,899 vol $15.40 each |
1,211,761 | |
Filed 2018-03-09 Tx date 2018-03-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Enhanced Ltd (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-63,558,264
-4,127,160 vol $15.40 each |
2,961,296 | |
Filed 2018-03-09 Tx date 2018-03-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners LP (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$108,826,086
+7,066,629 vol $15.40 each |
7,215,361 | |
Filed 2018-03-09 Tx date 2018-03-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners Enhanced LP (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-16,917,978
-1,098,570 vol $15.40 each |
405,317 | |
Filed 2018-01-30 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-30,146.40
-1,264 vol $23.85 each |
37,237 | |
Filed 2018-01-30 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-37,134.45
-1,557 vol $23.85 each |
||
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-8,191 vol |
45,614 | |
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$101,744
+4,266 vol $23.85 each |
16,037 | |
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$195,355
+8,191 vol $23.85 each |
16,759 | |
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-87,028.65
-3,649 vol $23.85 each |
13,110 | |
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-4,266 vol |
44,394 | |
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-43,550.10
-1,826 vol $23.85 each |
14,211 | |
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-4,095 vol |
50,687 | |
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-37,134.45
-1,557 vol $23.85 each |
36,944 | |
Filed 2018-01-10 Tx date 2018-01-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$97,665
+4,095 vol $23.85 each |
38,501 | |
Filed 2018-01-05 Tx date 2018-01-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$899,316
+43,278 vol $20.78 each |
43,278 | |
Filed 2018-01-05 Tx date 2018-01-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-43,278 vol |
86,560 | |
Filed 2018-01-05 Tx date 2018-01-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-306,089.40
-14,730 vol $20.78 each |
28,548 | |
Filed 2018-01-05 Tx date 2017-01-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-01-03 Tx date 2017-06-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$4,653
+269 vol $17.30 each |
18,166 | |
Filed 2018-01-03 Tx date 2017-12-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,503 vol |
53,045 | |
Filed 2018-01-03 Tx date 2017-12-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,804 vol |
55,858 | |
Filed 2018-01-03 Tx date 2017-12-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$27,491
+1,323 vol $20.78 each |
21,349 | |
Filed 2018-01-03 Tx date 2017-09-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$26,653
+1,860 vol $14.33 each |
20,026 | |
Filed 2018-01-03 Tx date 2017-12-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,503 vol |
33,020 | |
Filed 2017-11-21 Tx date 2017-11-16 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson International Ltd (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,540,963
+245,960 vol $14.40 each |
3,052,660 | |
Filed 2017-11-21 Tx date 2017-11-16 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Separately Managed Account (Control or Direction)
|
Equity Swap - Long Position
70 - Acquisition or disposition (writing) of third party derivative
|
$-3,726,030.75
-259,500 vol $14.36 each |
0 | |
Filed 2017-11-21 Tx date 2017-11-16 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-159,757.7361
-11,103 vol $14.39 each |
148,732 | |
Filed 2017-11-21 Tx date 2017-11-16 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners Enhanced LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,793,063.0231
-333,113 vol $14.39 each |
1,503,887 | |
Filed 2017-11-21 Tx date 2017-11-16 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Enhanced Ltd (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,414,542
+98,256 vol $14.40 each |
7,088,456 | |
Filed 2017-11-21 Tx date 2017-11-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$143,300
+10,000 vol $14.33 each |
63,042 | |
Filed 2017-10-04 Tx date 2017-09-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,239
+2,180 vol $14.33 each |
51,542 | |
Filed 2017-10-04 Tx date 2017-09-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$37,487
+2,616 vol $14.33 each |
54,054 | |
Filed 2017-10-04 Tx date 2017-09-29 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,239
+2,180 vol $14.33 each |
31,517 | |
Filed 2017-08-25 Tx date 2017-08-23 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$707,000
+50,000 vol $14.14 each |
74,000 | |
Filed 2017-08-25 Tx date 2017-08-23 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
$-707,000
-50,000 vol $14.14 each |
100,000 | |
Filed 2017-08-25 Tx date 2017-08-23 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-242,854.50
-17,175 vol $14.14 each |
56,825 | |
Filed 2017-08-24 Tx date 2017-08-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-80,471.05
-5,687 vol $14.15 each |
34,406 | |
Filed 2017-08-24 Tx date 2017-08-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$70,315
+4,900 vol $14.35 each |
53,042 | |
Filed 2017-08-24 Tx date 2017-08-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$72,981
+5,100 vol $14.31 each |
48,142 | |
Filed 2017-08-24 Tx date 2017-08-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
$-300,645.05
-21,247 vol $14.15 each |
54,782 | |
Filed 2017-08-24 Tx date 2017-08-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$300,645
+21,247 vol $14.15 each |
40,093 | |
Filed 2017-08-14 Tx date 2017-08-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$224,617
+14,614 vol $15.37 each |
14,614 | |
Filed 2017-08-14 Tx date 2017-08-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-14,614 vol |
53,805 | |
Filed 2017-08-14 Tx date 2017-08-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-92,927.02
-6,046 vol $15.37 each |
8,568 | |
Filed 2017-08-14 Tx date 2016-08-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-08-11 Tx date 2017-08-11 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Indirect Ownership)
|
Bonds Corporate Bond 5.875% 05/15/2023
10 - Acquisition or disposition in the public market
|
$
-$8,000,000 vol $84.50 each |
||
Filed 2017-08-11 Tx date 2017-08-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Indirect Ownership)
|
Bonds Corporate Bond 6.125% 04/15/2025
10 - Acquisition or disposition in the public market
|
$
-$13,000,000 vol $84.92 each |
$90,000,000 | |
Filed 2017-08-11 Tx date 2017-08-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Indirect Ownership)
|
Bonds Corporate Bond 6.125% 04/15/2025
10 - Acquisition or disposition in the public market
|
$
-$37,000,000 vol $84.00 each |
$103,000,000 | |
Filed 2017-08-11 Tx date 2017-08-11 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Indirect Ownership)
|
Bonds Corporate Bond 5.875% 05/15/2023
10 - Acquisition or disposition in the public market
|
$
-$8,000,000 vol $84.50 each |
$0 | |
Filed 2017-08-11 Tx date 2017-08-10 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Indirect Ownership)
|
Bonds Corporate Bond 5.875% 05/15/2023
10 - Acquisition or disposition in the public market
|
$
-$2,000,000 vol $84.63 each |
$8,000,000 | |
Filed 2017-08-09 Tx date 2017-08-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners LP (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,482,939.5675
-578,665 vol $14.66 each |
159,835 | |
Filed 2017-08-09 Tx date 2017-08-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Separately Managed Account (Indirect Ownership)
|
Equity Swap - Long Position
70 - Acquisition or disposition (writing) of third party derivative
|
$-8,806,573.80
-603,000 vol $14.60 each |
259,500 | |
Filed 2017-08-09 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Separately Managed Account (Control or Direction)
|
Equity Swap - Long Position
00 - Opening Balance-Initial SEDI Report
|
862,500 | ||
Filed 2017-08-09 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Separately Managed Account (Control or Direction)
|
Equity Swap - Long Position
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-08-09 Tx date 2017-08-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners Premium LP (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-362,089.65
-24,700 vol $14.66 each |
0 | |
Filed 2017-07-06 Tx date 2017-06-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,243
+1,806 vol $17.30 each |
49,362 | |
Filed 2017-07-06 Tx date 2017-06-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,261
+1,807 vol $17.30 each |
29,337 | |
Filed 2017-07-06 Tx date 2017-06-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$37,489
+2,167 vol $17.30 each |
51,438 | |
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: UTMA Account 1 (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
125 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
17,897 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Separately Managed Account (Control or Direction)
|
Equity Swap - Long Position
00 - Opening Balance-Initial SEDI Report
|
1 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: UTMA Account 3 (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: UTMA Account 2 (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: UTMA Account 1 (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: UTMA Account 4 (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
30 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: UTMA Account 3 (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
35 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: UTMA Account 2 (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
30 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Recovery Master Fund (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
2,500,000 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners Premium LP (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
24,700 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners LP (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
738,500 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Partners Enhanced LP (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,837,000 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson International Ltd (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
2,806,700 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Enhanced Ltd (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
6,990,200 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Advantage Plus Master Ltd (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
4,836,200 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Advantage Master Ltd (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,709,100 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Control or Direction)
|
Bonds Corporate Bond 6.125% 04/15/2025
00 - Opening Balance-Initial SEDI Report
|
$140,000,000 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Control or Direction)
|
Bonds Corporate Bond 5.875% 05/15/2023
00 - Opening Balance-Initial SEDI Report
|
$10,000,000 | ||
Filed 2017-06-26 Tx date 2017-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Paulson, John
4 - Director of Issuer
Holder: Paulson Credit Opportunities Master Ltd (Control or Direction)
|
Bonds Corporate Bond 5.375% 03/15/2020
00 - Opening Balance-Initial SEDI Report
|
$75,000,000 | ||
Filed 2017-06-12 Tx date 2017-06-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-17,930 vol |
48,660 | |
Filed 2017-06-12 Tx date 2017-06-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-77,049.09
-6,159 vol $12.51 each |
11,771 | |
Filed 2017-06-12 Tx date 2017-06-07 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$224,304
+17,930 vol $12.51 each |
17,930 | |
Filed 2017-06-12 Tx date 2016-06-15 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-05-15 Tx date 2017-05-11 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$278,000
+20,000 vol $13.90 each |
43,042 | |
Filed 2017-05-15 Tx date 2017-05-10 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-12,230 vol |
76,029 | |
Filed 2017-05-15 Tx date 2017-05-10 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-31,790.54
-3,274 vol $9.71 each |
18,846 | |
Filed 2017-05-15 Tx date 2017-05-10 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$118,753
+12,230 vol $9.71 each |
22,120 | |
Filed 2017-05-09 Tx date 2017-05-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-11,190 vol |
27,530 | |
Filed 2017-05-09 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
38,720 | |
Filed 2017-05-09 Tx date 2017-05-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-20,749.68
-2,148 vol $9.66 each |
23,042 | |
Filed 2017-05-09 Tx date 2017-05-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$108,095
+11,190 vol $9.66 each |
25,190 | |
Filed 2017-05-08 Tx date 2017-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$161,573
+16,726 vol $9.66 each |
17,796 | |
Filed 2017-05-08 Tx date 2017-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-47,372.64
-4,904 vol $9.66 each |
12,892 | |
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
47,556 | |
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
43,228 | |
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,046 vol |
||
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
49,271 | |
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Power, Robert Noel
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
51,627 | |
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kavanagh, Sarah Baldwin
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
39,864 | |
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
42,132 | |
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
25,406 | |
Filed 2017-05-08 Tx date 2017-05-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+25,406 vol |
25,406 | |
Filed 2017-05-08 Tx date 2017-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-16,726 vol |
0 | |
Filed 2017-05-08 Tx date 2017-05-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
+16,726 vol |
||
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
-12,803 vol |
||
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-16,726 vol |
0 | |
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-16,726 vol |
||
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-16,726 vol |
||
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$123,676
+12,803 vol $9.66 each |
12,803 | |
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
-12,803 vol |
||
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$123,676
+12,803 vol $9.66 each |
||
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$123,676
+12,803 vol $9.66 each |
||
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Holder: ValueAct Capital Master Fund, L.P. (Control or Direction)
|
Common Shares
97 - Other
|
+12,803 vol |
||
Filed 2017-05-05 Tx date 2017-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Holder: ValueAct Capital Master Fund, L.P. (Control or Direction)
|
Common Shares
97 - Other
|
+12,803 vol |
||
Filed 2017-04-10 Tx date 2017-03-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$34,490
+3,127 vol $11.03 each |
23,865 | |
Filed 2017-04-10 Tx date 2017-03-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ingram, Robert A.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$23,383
+2,120 vol $11.03 each |
85,263 | |
Filed 2017-04-10 Tx date 2017-03-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$23,427
+2,124 vol $11.03 each |
13,314 | |
Filed 2017-04-10 Tx date 2017-03-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$27,133
+2,460 vol $11.03 each |
22,150 | |
Filed 2017-03-30 Tx date 2017-03-28 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+63,742 vol |
88,259 | |
Filed 2017-03-18 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$257,280
+24,000 vol $10.72 each |
24,000 | |
Filed 2017-03-18 Tx date 2016-08-22 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-03-18 Tx date 2017-03-15 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$108,000
+10,000 vol $10.80 each |
14,000 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$128,475,502
+2,696,233 vol $47.65 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$3,232,766
+67,844 vol $47.65 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$202,099,708
+4,241,337 vol $47.65 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
Listed Calls (including Options to Purchase )
70 - Acquisition or disposition (writing) of third party derivative
|
$-6,343.80
-21,146 vol $0.30 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
Listed Calls (including Options to Purchase )
70 - Acquisition or disposition (writing) of third party derivative
|
$-8,088.60
-26,962 vol $0.30 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-96,581,430
-8,780,130 vol $11.00 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
Listed Calls (including Options to Purchase )
70 - Acquisition or disposition (writing) of third party derivative
|
$-203.40
-678 vol $0.30 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
Listed Calls (including Options to Purchase )
70 - Acquisition or disposition (writing) of third party derivative
|
$-12,724.20
-42,414 vol $0.30 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,662,183
-2,605,653 vol $11.00 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-343,519
-31,229 vol $11.00 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-73,671,620
-6,697,420 vol $11.00 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
-1,114 vol |
0 | |
Filed 2017-03-17 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Holder: ValueAct Capital Master Fund, L.P. (Control or Direction)
|
Common Shares
97 - Other
|
+2,963 vol |
16,937,431 | |
Filed 2017-03-17 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Holder: ValueAct Capital Master Fund, L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
+2,500,000 vol |
16,934,468 | |
Filed 2017-03-17 Tx date 2017-03-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Holder: ValueAct Capital Master Fund, L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
+500,000 vol |
14,434,468 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$100,760,022
+2,114,586 vol $47.65 each |
0 | |
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$85,957,920
+2,114,586 vol $40.65 each |
||
Filed 2017-03-17 Tx date 2017-03-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$85,957,920
+2,114,586 vol $40.65 each |
||
Filed 2017-03-06 Tx date 2017-01-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-03-06 Tx date 2017-03-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$2,169,352
+150,859 vol $14.38 each |
150,859 | |
Filed 2017-03-06 Tx date 2017-01-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+12,799 vol |
66,590 | |
Filed 2017-03-06 Tx date 2016-06-15 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
53,791 | ||
Filed 2017-03-06 Tx date 2017-01-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+8,534 vol |
8,534 | |
Filed 2017-03-06 Tx date 2016-06-15 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-03-06 Tx date 2017-03-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$451,963
+31,430 vol $14.38 each |
31,430 | |
Filed 2017-03-06 Tx date 2017-03-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$433,902
+30,174 vol $14.38 each |
30,174 | |
Filed 2017-03-06 Tx date 2016-08-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-03-06 Tx date 2017-03-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$867,761
+60,345 vol $14.38 each |
99,814 | |
Filed 2017-03-06 Tx date 2016-06-15 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eldessouky, Osama
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-11 Tx date 2017-01-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+4,096 vol |
12,571 | |
Filed 2017-01-11 Tx date 2017-01-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+24,575 vol |
68,419 | |
Filed 2017-01-11 Tx date 2017-01-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+8,192 vol |
34,498 | |
Filed 2017-01-11 Tx date 2017-01-06 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+12,287 vol |
24,517 | |
Filed 2017-01-06 Tx date 2017-01-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+129,838 vol |
129,838 | |
Filed 2017-01-06 Tx date 2017-01-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-06 Tx date 2017-01-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+41,002 vol |
41,002 | |
Filed 2017-01-06 Tx date 2017-01-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Humphries, William Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-06 Tx date 2017-01-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$170,535
+11,190 vol $15.24 each |
11,190 | |
Filed 2017-01-06 Tx date 2017-01-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
4,000 | ||
Filed 2017-01-06 Tx date 2017-01-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
DE SCHUTTER, Richard Urbain
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-06 Tx date 2016-12-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$24,988
+1,721 vol $14.52 each |
19,690 | |
Filed 2017-01-06 Tx date 2016-12-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$33,744
+2,324 vol $14.52 each |
20,738 | |
Filed 2017-01-06 Tx date 2016-12-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ingram, Robert A.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$21,242
+1,463 vol $14.52 each |
83,143 | |
Filed 2016-12-22 Tx date 2016-08-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$58,850
+2,500 vol $23.54 each |
10,000 | |
Filed 2016-12-22 Tx date 2016-08-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-2,500 vol |
42,935 | |
Filed 2016-12-22 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-108,216
-6,012 vol $18.00 each |
15,799 | |
Filed 2016-12-22 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-117,090
-6,505 vol $18.00 each |
||
Filed 2016-12-22 Tx date 2016-08-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-19,632.36
-834 vol $23.54 each |
9,166 | |
Filed 2016-12-19 Tx date 2016-12-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$73,650
+5,000 vol $14.73 each |
9,000 | |
Filed 2016-12-16 Tx date 2016-12-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-49,883,793.30
-3,359,178 vol $14.85 each |
2,605,653 | |
Filed 2016-12-16 Tx date 2016-12-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
70 - Acquisition or disposition (writing) of third party derivative
|
$25,315
+2,531,559 vol $0.01 each |
0 | |
Filed 2016-12-16 Tx date 2016-12-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
70 - Acquisition or disposition (writing) of third party derivative
|
$28,378
+2,837,875 vol $0.01 each |
0 | |
Filed 2016-12-16 Tx date 2016-12-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
70 - Acquisition or disposition (writing) of third party derivative
|
$631.22
+63,122 vol $0.01 each |
0 | |
Filed 2016-12-16 Tx date 2016-12-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
70 - Acquisition or disposition (writing) of third party derivative
|
$36,874
+3,687,444 vol $0.01 each |
0 | |
Filed 2016-12-16 Tx date 2016-12-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,745,053.20
-117,512 vol $14.85 each |
31,229 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-38,441 vol |
104,700 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-12,645 vol |
32,790 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-117,090
-6,505 vol $18.00 each |
13,640 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$227,610
+12,645 vol $18.00 each |
20,145 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-28,325 vol |
73,270 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-264,366
-14,687 vol $18.00 each |
36,413 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$509,850
+28,325 vol $18.00 each |
51,100 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-358,776
-19,932 vol $18.00 each |
76,142 | |
Filed 2016-12-12 Tx date 2016-12-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$691,938
+38,441 vol $18.00 each |
96,074 | |
Filed 2016-11-14 Tx date 2016-11-04 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$18,023
+817 vol $22.06 each |
||
Filed 2016-11-14 Tx date 2016-11-04 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-18,023.02
-817 vol $22.06 each |
22,775 | |
Filed 2016-11-10 Tx date 2016-11-04 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$18,023
+817 vol $22.06 each |
24,409 | |
Filed 2016-11-10 Tx date 2016-11-04 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-1,575 vol |
101,595 | |
Filed 2016-11-10 Tx date 2016-11-04 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$34,744
+1,575 vol $22.06 each |
23,592 | |
Filed 2016-10-06 Tx date 2016-09-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,376 vol |
18,414 | |
Filed 2016-10-06 Tx date 2016-09-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,018 vol |
17,969 | |
Filed 2016-10-06 Tx date 2016-09-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ingram, Robert A.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+865 vol |
81,680 | |
Filed 2016-09-06 Tx date 2016-08-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
9,890 | ||
Filed 2016-09-06 Tx date 2016-08-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
8,475 | ||
Filed 2016-09-06 Tx date 2016-08-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Appio, Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
12,230 | ||
Filed 2016-09-02 Tx date 2016-08-22 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,000,000 vol |
1,000,000 | |
Filed 2016-09-02 Tx date 2016-08-22 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$4,311,000
+150,000 vol $28.74 each |
150,000 | |
Filed 2016-09-02 Tx date 2016-08-22 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-09-02 Tx date 2016-08-22 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Herendeen, Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-15 Tx date 2016-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-15 Tx date 2016-08-11 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$98,600
+4,000 vol $24.65 each |
4,000 | |
Filed 2016-08-15 Tx date 2016-08-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-15 Tx date 2016-08-10 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+39,469 vol |
39,469 | |
Filed 2016-08-12 Tx date 2016-08-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-31,496.52
-1,338 vol $23.54 each |
22,017 | |
Filed 2016-08-12 Tx date 2016-08-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+26,306 vol |
||
Filed 2016-08-12 Tx date 2016-08-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
$600,039
+26,306 vol $22.81 each |
26,306 | |
Filed 2016-08-12 Tx date 2016-08-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+43,844 vol |
43,844 | |
Filed 2016-08-12 Tx date 2016-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
-26 vol |
||
Filed 2016-08-12 Tx date 2016-07-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+2,580 vol |
||
Filed 2016-08-12 Tx date 2016-08-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+2,580 vol |
23,355 | |
Filed 2016-08-12 Tx date 2016-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
-26 vol |
||
Filed 2016-08-12 Tx date 2016-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-618.28
-26 vol $23.78 each |
1,070 | |
Filed 2016-08-12 Tx date 2016-07-27 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kavanagh, Sarah Baldwin
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$339,618
+14,458 vol $23.49 each |
14,458 | |
Filed 2016-08-12 Tx date 2016-08-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kavanagh, Sarah Baldwin
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$339,618
+14,458 vol $23.49 each |
||
Filed 2016-08-12 Tx date 2016-08-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
-1,338 vol |
||
Filed 2016-08-12 Tx date 2016-07-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-2,580 vol |
||
Filed 2016-08-12 Tx date 2016-08-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-2,580 vol |
103,170 | |
Filed 2016-08-11 Tx date 2016-08-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-11 Tx date 2016-06-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$4,531
+225 vol $20.14 each |
16,951 | |
Filed 2016-08-11 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
16,726 | |
Filed 2016-08-11 Tx date 2016-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Wechsler, Amy
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-11 Tx date 2016-06-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$6,283
+312 vol $20.14 each |
17,038 | |
Filed 2016-08-11 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
16,726 | |
Filed 2016-08-11 Tx date 2016-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Robertson, Russel Clark
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-11 Tx date 2016-08-03 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kavanagh, Sarah Baldwin
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$339,618
+14,458 vol $23.49 each |
14,458 | |
Filed 2016-08-11 Tx date 2016-07-22 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kavanagh, Sarah Baldwin
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-11 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
16,726 | |
Filed 2016-08-11 Tx date 2016-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
||
Filed 2016-08-11 Tx date 2016-06-14 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Karabelas, Argeris
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-11 Tx date 2016-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-1,096 vol |
16,726 | |
Filed 2016-08-11 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
17,822 | |
Filed 2016-08-11 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$408,114
+16,726 vol $24.40 each |
||
Filed 2016-08-11 Tx date 2016-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
-26 vol |
1,070 | |
Filed 2016-08-11 Tx date 2016-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+1,096 vol |
1,096 | |
Filed 2016-08-11 Tx date 2016-03-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-11 Tx date 2016-08-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackermann, Christina
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-07-21 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ingram, Robert A.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
79,735 | |
Filed 2016-07-21 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
17,822 | |
Filed 2016-07-21 Tx date 2016-06-13 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$97,600
+4,000 vol $24.40 each |
4,000 | |
Filed 2016-07-21 Tx date 2016-03-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-07-21 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Power, Robert Noel
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
26,221 | |
Filed 2016-07-21 Tx date 2016-06-30 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ingram, Robert A.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$21,751
+1,080 vol $20.14 each |
80,815 | |
Filed 2016-07-21 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$408,114
+16,726 vol $24.40 each |
17,822 | |
Filed 2016-07-20 Tx date 2015-05-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ubben, Jeffrey W.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-1,634 vol |
||
Filed 2016-07-20 Tx date 2015-05-22 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ubben, Jeffrey W.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,607 vol |
1,607 | |
Filed 2016-07-20 Tx date 2015-05-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ubben, Jeffrey W.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-1,634 vol |
0 | |
Filed 2016-07-20 Tx date 2015-05-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ubben, Jeffrey W.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-1,634 vol |
||
Filed 2016-07-20 Tx date 2015-05-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ubben, Jeffrey W.
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+1,510 vol |
1,510 | |
Filed 2016-07-18 Tx date 2014-10-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ubben, Jeffrey W.
4 - Director of Issuer
Direct Ownership
|
Rights Deferred Share Units (DSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-07-18 Tx date 2014-10-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ubben, Jeffrey W.
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-07-06 Tx date 2015-08-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-07-06 Tx date 2016-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
-1,148 vol |
16,726 | |
Filed 2016-07-06 Tx date 2016-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+1,114 vol |
1,114 | |
Filed 2016-06-22 Tx date 2016-06-17 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$374,996
+16,726 vol $22.42 each |
17,874 | |
Filed 2016-06-15 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$-78,427,880.154
-2,114,586 vol $37.09 each |
-2,114,586 | |
Filed 2016-06-15 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$-78,428,251.044
-2,114,596 vol $37.09 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$2,259,767
+63,122 vol $35.80 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$90,629,812
+2,531,559 vol $35.80 each |
0 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$90,629,812
+2,531,559 vol $35.80 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$90,629,812
+2,531,559 vol $35.80 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$101,595,924
+2,837,875 vol $35.80 each |
0 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$101,595,924
+2,837,875 vol $35.80 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$101,595,924
+2,837,875 vol $35.80 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$2,259,767
+63,122 vol $35.80 each |
0 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$2,259,767
+63,122 vol $35.80 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$132,010,495
+3,687,444 vol $35.80 each |
0 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$132,010,495
+3,687,444 vol $35.80 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
$132,010,495
+3,687,444 vol $35.80 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$-78,428,251.044
-2,114,596 vol $37.09 each |
-2,114,596 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$-78,427,880.154
-2,114,586 vol $37.09 each |
||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$-78,427,880.154
-2,114,586 vol $37.09 each |
||
Filed 2016-06-14 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$-100,000,585.737
-2,696,233 vol $37.09 each |
-2,696,233 | |
Filed 2016-06-14 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$-2,516,266.116
-67,844 vol $37.09 each |
-67,844 | |
Filed 2016-06-14 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
70 - Acquisition or disposition (writing) of third party derivative
|
$-157,306,947.993
-4,241,337 vol $37.09 each |
-4,241,337 | |
Filed 2016-06-14 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
$-75,946.77
-2,531,559 vol $0.03 each |
0 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
$-85,136.25
-2,837,875 vol $0.03 each |
0 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
$-1,893.66
-63,122 vol $0.03 each |
0 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
$-110,623.32
-3,687,444 vol $0.03 each |
0 | |
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
Listed Calls (including Options to Purchase )
70 - Acquisition or disposition (writing) of third party derivative
|
$84,584
+21,146 vol $4.00 each |
21,146 | |
Filed 2016-06-14 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
Listed Calls (including Options to Purchase )
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
Listed Calls (including Options to Purchase )
70 - Acquisition or disposition (writing) of third party derivative
|
$107,848
+26,962 vol $4.00 each |
26,962 | |
Filed 2016-06-14 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
Listed Calls (including Options to Purchase )
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
Listed Calls (including Options to Purchase )
70 - Acquisition or disposition (writing) of third party derivative
|
$2,712
+678 vol $4.00 each |
678 | |
Filed 2016-06-14 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
Listed Calls (including Options to Purchase )
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-14 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
Listed Calls (including Options to Purchase )
70 - Acquisition or disposition (writing) of third party derivative
|
$169,656
+42,414 vol $4.00 each |
42,414 | |
Filed 2016-06-14 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
Listed Calls (including Options to Purchase )
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-13 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-13 Tx date 2016-06-10 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,944,960
+202,000 vol $24.48 each |
202,000 | |
Filed 2016-06-13 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-06-13 Tx date 2016-06-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+682,652 vol |
682,652 | |
Filed 2016-05-16 Tx date 2016-05-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Rosiello, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$2,118,426
+84,975 vol $24.93 each |
105,750 | |
Filed 2016-05-16 Tx date 2016-05-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$2,875,027
+115,324 vol $24.93 each |
143,141 | |
Filed 2016-05-16 Tx date 2016-05-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Chai-Onn, Robert Roswell
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$1,513,176
+60,697 vol $24.93 each |
62,375 | |
Filed 2016-05-16 Tx date 2016-05-12 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Whitaker, Anne
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$945,719
+37,935 vol $24.93 each |
45,435 | |
Filed 2016-05-11 Tx date 2015-10-25 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Morfit, Garrison Mason
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,883 vol |
||
Filed 2016-05-11 Tx date 2015-08-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$281,156
+1,148 vol $244.91 each |
1,148 | |
Filed 2016-05-11 Tx date 2015-08-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,148 vol |
||
Filed 2016-05-11 Tx date 2015-10-25 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Morfit, Garrison Mason
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$218,729
+1,883 vol $116.16 each |
1,883 | |
Filed 2016-05-10 Tx date 2015-10-25 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Morfit, Garrison Mason
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-05-10 Tx date 2015-08-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,148 vol |
1,148 | |
Filed 2016-05-10 Tx date 2015-08-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-05-10 Tx date 2015-08-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Holder: ValueAct Capital Master Fund, L.P. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
13,934,468 | ||
Filed 2016-05-10 Tx date 2015-08-19 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Hale, David Robert
4 - Director of Issuer
Holder: ValueAct Capital Master Fund, L.P. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-05-10 Tx date 2015-10-25 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Morfit, Garrison Mason
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
+1,883 vol |
1,883 | |
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$12,190,432
+373,367 vol $32.65 each |
373,367 | |
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$30,476,032
+933,416 vol $32.65 each |
||
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
$30,476,032
+933,416 vol $32.65 each |
933,416 | |
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Papa, Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Melas-Kyriazi, Theo
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$24,985
+950 vol $26.30 each |
80,339 | |
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ingram, Robert A.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$24,353
+926 vol $26.30 each |
63,009 | |
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Farmer, Ron
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$26,247
+998 vol $26.30 each |
22,915 | |
Filed 2016-05-04 Tx date 2016-05-02 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Provencio, Norma Ann
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$31,244
+1,188 vol $26.30 each |
57,196 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
5,964,831 | ||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
148,741 | ||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
6,697,420 | ||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
-2,531,559 vol |
-2,531,559 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
-2,837,875 vol |
-2,837,875 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
8,780,130 | ||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
-63,122 vol |
-63,122 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
70 - Acquisition or disposition (writing) of third party derivative
|
-3,687,444 vol |
-3,687,444 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Puts (including Private Options to Sell) Exercise US$60.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
+2,531,559 vol |
2,531,559 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
+2,531,559 vol |
||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
+2,837,875 vol |
2,837,875 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
+63,122 vol |
63,122 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
70 - Acquisition or disposition (writing) of third party derivative
|
+3,687,444 vol |
3,687,444 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$95.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
70 - Acquisition or disposition (writing) of third party derivative
|
-2,531,559 vol |
-2,531,559 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
70 - Acquisition or disposition (writing) of third party derivative
|
-2,837,875 vol |
-2,837,875 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square International, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
70 - Acquisition or disposition (writing) of third party derivative
|
-63,122 vol |
-63,122 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square II, L.P. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
70 - Acquisition or disposition (writing) of third party derivative
|
-3,687,444 vol |
-3,687,444 | |
Filed 2016-03-31 Tx date 2016-03-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ackman, William A.
4 - Director of Issuer
Holder: Pershing Square Holdings, Ltd. (Control or Direction)
|
OTC Calls (including Private Options to Purchase) Exercise US$165.00
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-15 Tx date 2016-03-11 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$76,226
+1,096 vol $69.55 each |
1,096 | |
Filed 2016-03-15 Tx date 2016-03-11 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$76,226
+1,096 vol $69.55 each |
1,096 | |
Filed 2016-03-15 Tx date 2016-03-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ross Sr., Thomas
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-15 Tx date 2016-03-08 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Eshelman, Fredric
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-02-22 Tx date 2016-02-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Schiller, Howard
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
$-558,027.90
-6,102 vol $91.45 each |
1,506 | |
Filed 2016-02-22 Tx date 2016-02-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Schiller, Howard
4 - Director of Issuer
Direct Ownership
|
Performance Share Units
57 - Exercise of rights
|
$-9,145,000
-100,000 vol $91.45 each |
0 | |
Filed 2016-02-22 Tx date 2016-02-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Schiller, Howard
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-4,741,316.70
-51,846 vol $91.45 each |
335,278 | |
Filed 2016-02-22 Tx date 2016-02-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Schiller, Howard
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$9,145,000
+100,000 vol $91.45 each |
387,124 | |
Filed 2016-02-22 Tx date 2016-02-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Schiller, Howard
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-205,305.25
-2,245 vol $91.45 each |
287,124 | |
Filed 2016-02-22 Tx date 2016-02-18 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Schiller, Howard
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$558,027
+6,102 vol $91.45 each |
289,369 | |
Filed 2016-01-28 Tx date 2016-01-26 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-295,146.66
-3,317 vol $88.98 each |
57,633 | |
Filed 2016-01-28 Tx date 2016-01-26 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$857,055
+9,632 vol $88.98 each |
60,950 | |
Filed 2016-01-28 Tx date 2016-01-26 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
$-857,055.36
-9,632 vol $88.98 each |
27,817 | |
Filed 2016-01-28 Tx date 2014-05-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
$29,468,250
+225,000 vol $130.97 each |
450,000 | |
Filed 2016-01-28 Tx date 2014-05-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
$9,822,750
+75,000 vol $130.97 each |
||
Filed 2016-01-28 Tx date 2014-01-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+225,000 vol |
225,000 | |
Filed 2016-01-28 Tx date 2014-01-09 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Kellen, Ari
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+75,000 vol |
||
Filed 2016-01-05 Tx date 2015-12-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Pearson, J. Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
97 - Other
|
$-1,063,173.24
-14,412 vol $73.77 each |
1,561,582 | |
Filed 2016-01-04 Tx date 2015-12-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Ingram, Robert A.
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$24,294
+239 vol $101.65 each |
62,083 | |
Filed 2016-01-04 Tx date 2015-07-01 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Schiller, Howard
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$343,729
+1,506 vol $228.24 each |
7,608 | |
Filed 2016-01-04 Tx date 2015-12-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Provencio, Norma Ann
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$34,967
+344 vol $101.65 each |
56,008 | |
Filed 2016-01-04 Tx date 2015-12-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Melas-Kyriazi, Theo
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$24,904
+245 vol $101.65 each |
79,389 | |
Filed 2016-01-04 Tx date 2015-12-31 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Farmer, Ron
4 - Director of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
56 - Grant of rights
|
$26,225
+258 vol $101.65 each |
21,917 | |
Filed 2015-11-24 Tx date 2015-11-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
JORN, DEBORA
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$-124,670
-1,370 vol $91.00 each |
6,928 | |
Filed 2015-11-24 Tx date 2015-11-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
JORN, DEBORA
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
57 - Exercise of rights
|
$-240,331
-2,641 vol $91.00 each |
27,884 | |
Filed 2015-11-24 Tx date 2015-05-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
JORN, DEBORA
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
30,525 | ||
Filed 2015-11-24 Tx date 2015-05-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
JORN, DEBORA
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Units (RSUs)
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-11-24 Tx date 2015-11-20 |
$VRX
Valeant Pharmaceuticals International, Inc. |
JORN, DEBORA
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$240,331
+2,641 vol $91.00 each |
8,298 | |
Filed 2015-11-09 Tx date 2015-11-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Pearson, J. Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-61,354,447.70
-800,345 vol $76.66 each |
1,283,986 | |
Filed 2015-11-09 Tx date 2015-11-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Pearson, J. Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
-350,000 vol |
933,986 | |
Filed 2015-11-09 Tx date 2015-11-05 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Pearson, J. Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-10,980,522.18
-147,054 vol $74.67 each |
2,084,331 | |
Filed 2015-11-04 Tx date 2015-10-25 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Morfit, Garrison Mason
4 - Director of Issuer
Holder: ValueAct Co-Invest Master Fund, L.P. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,059,793 | ||
Filed 2015-11-04 Tx date 2015-10-25 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Morfit, Garrison Mason
4 - Director of Issuer
Holder: ValueAct Capital Master Fund, L.P. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
13,934,468 | ||
Filed 2015-10-27 Tx date 2015-10-26 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Valeant Pharmaceuticals International, Inc.
1 - Issuer
Direct Ownership
|
Common Shares
38 - Redemption, retraction, cancellation, repurchase
|
-200,000 vol |
0 | |
Filed 2015-10-27 Tx date 2015-10-21 |
$VRX
Valeant Pharmaceuticals International, Inc. |
Valeant Pharmaceuticals International, Inc.
1 - Issuer
Direct Ownership
|
Common Shares
38 - Redemption, retraction, cancellation, repurchase
|